Halozyme Therapeutics | HALO - Собственный капитал и резервы





Собственный капитал и резервы Изменить Дата
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amarin USD 449.41M 9.87M 2026-03
Amgen USD 9.19B 532M 2026-03
Baxter International USD 6.04B 86M 2026-03
Cara Therapeutics USD 20.95M 6.92M 2025-12
Cytokinetics USD -826.57M 166.94M 2026-03
DBV Technologies USD 168.77M 115.92M 2025-12
Eli Lilly USD 31.2B 4.66B 2026-03
Esperion Therapeutics USD -307.93M 5.97M 2026-03
Halozyme Therapeutics USD 219.64M 170.82M 2026-03
Intrexon USD 43.17M 75.33M 2024-06
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
MannKind USD -59.2M 8.17M 2026-03
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Pfizer USD 90.1B 3.63B 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
United Therapeutics USD 5.9B 1.2B 2026-03
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12